Study of CT0596 for Relapsed or Refractory Myeloma
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests a new CAR-T cell therapy called CT0596 for people with multiple myeloma or plasma cell leukemia that has come back or stopped responding to treatment. The goal is to see if this therapy can help control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have had at least 3 prior treatments for multiple myeloma, including a proteasome inhibitor and an immunomodulator (for plasma cell leukemia, at least 1 prior treatment is needed).
- Your disease must be getting worse despite your last treatment.
- You must be age 18 or older and able to care for yourself (ECOG score 0 or 1).
- You cannot have had a stem cell transplant from a donor, active infections, or certain other cancers.
- You must be willing to use effective birth control for 1 year after the study drug.
- You cannot have had CAR-T cell therapy in the last 28 days.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new cell therapy called CT0596 for people with multiple myeloma or plasma cell leukemia that is not responding to standard treatments or has come back. The therapy uses your own immune cells that are modified to fight the cancer.
This study tests a new type of cell therapy called CAR-T, which uses your own immune cells to fight the cancer. It is for people with multiple myeloma that has come back or not responded to at least three previous treatments.
This trial tests two new CAR-T cell therapies (LCAR-M61S and LCAR-M61D) for people whose multiple myeloma has come back or stopped responding to at least three prior treatments. The treatment uses your own immune cells that are modified to find and attack cancer cells.
This trial tests a new type of cell therapy (CAR-T cells) that targets two proteins, BCMA and GPRC5D, on myeloma cells. It aims to see if it is safe and effective for people whose multiple myeloma has come back or stopped responding to at least three previous treatments.
This trial tests a new type of immune cell therapy (CAR-T cells boosted with a protein called IL-15) for people with multiple myeloma or plasma cell leukemia that has not responded to standard treatments or has come back. The goal is to see if these enhanced cells can better fight the cancer.
This Phase 1 trial tests a CAR T-cell treatment made to target a protein called GPRC5D on myeloma cells. It may help patients whose multiple myeloma or plasma cell leukemia has come back or stopped responding to prior treatments.
Hear when a new Relapsed/Refractory Multiple Myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.